Work

The efficacy and safety of radiofrequency ablation for trachea-adjacent cT1N0M0 papillary thyroid carcinoma: a five-year follow-up study

Year: 2026
Type: article
Study design: Observational Study
Abstract: Objective: To assess the efficacy and safety of ultrasound-guided radiofrequency ablation (RFA) in treating clinical-T1N0M0 (cT1N0M0) papillary thyroid carcinoma (PTC) adjacent to the trachea. Methods: This study retrospectively analyzed 423 patients (563 cT1N0M0 PTC nodules) who underwent ultrasound-guided RFA at Xuanwu Hospital, Capital Medical University, between October 2020 and December 2023. All cases were confirmed as non-aggressive, without distant metastasis or concurrent malignancies, by RFA and imaging evidence. Based on the distance between the lesion and trachea (≤2 mm), the lesions were categorized into a trachea-adjacent group and a trachea-distant group. The study aimed to evaluate the efficacy and safety of RFA for cT1N0M0 PTC adjacent to the trachea. The rates of local recurrence, new lesions, lymph node metastasis (LNM), and complications are recorded and compared. Results: 1.Patient Distribution: The trachea-adjacent group included 102 cases (18.1%), while the trachea-distant group included 461 cases (81.9%). 2. There was no significant difference in the complete absorption rate and Disease-free survival rate (DFS) between the trachea-adjacent group and the trachea-distant group at different follow-up times (all p >0.05). 3. Disease Progression: Disease progression occurred in 10 patients (2.36%), including 8 cases of new lesions, 0 cases of residual lesions and 2 cases of LNM. The 8 new lesions happened at a mean detection time of (22.2 ± 1.1) months, with all underwent re-RFA, achieving complete absorption in all cases. After a mean follow-up of (37.6 ± 3.5) months, no additional new lesions or LNM were detected. There are no LNM in the trachea-adjacent group. 4. Comparative Outcomes Between Groups: No significant differences were observed between the trachea-adjacent and trachea-distant groups in terms of complete absorption rate, disease progression rate (all p > 0.05). 5. Complications and Risk Factors: Complications occurred in 15 patients (3.5%), with 11 cases in the trachea-adjacent group and 4 in the trachea-distant group, demonstrating a statistically significant difference ( p < 0.05). All complications occurred within 3 months post-RFA. Multivariate Logistic regression analysis identified tumor location in the thyroid dorsal region and the extent of tracheal contact as independent risk factors for complications. Conclusion: With precise preoperative evaluation, operative techniques and assessment, RFA is a relatively effective and safe treatment for cT1N0M0 PTC located adjacent to the trachea, providing patients with an additional therapeutic option.
Source: BMC Cancer
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,390
OpenAlex ID: W7167909635
FWCI:
Cites: 21
Cited by:
Related to: 10